Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know. Wishful thinking...
Man I hope that 800,000 order goes through. Looks like they are meeting in the middle at .095...
Thanks for reminding us again. They make money and I make money. But it is getting old.
They were accumulating at .05 .06
We just need real buyers. If this could get some attention and real money it would move quick. I really think the shares are being held tight by those that actually have them. I know I have my 100,000 share holding tight. I will also continue to add to it monthly.
Right. If it was real someone should grow some and up it to .10 only 8k more..lol
level 2 shows it.
MPID
Bid Price
Size
Date/Time
CDEL 0.0903 38,300 11:52
NITE 0.09 882,700 11:38
CSTI 0.0851 34,000 11:54
MPID
Ask Price
Size
Date/Time
CDEL 0.0999 22,200 11:52
NITE 0.101 10,000 12:15
WDCO 0.11 5,000 06/22
Someone bought up all the left over .10 yesterday.
Well that is how it goes. Some win and just as many lose. I am up on this one and had cashed out at .30 and back in at .05-.09 not everyone can win.
Looks like our wall is .10
David Johnson Einstein, MD
Oncology Boston, MA
Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative Fellow, BIDMC
Office Address
800 Washington St
Boston, MA 02111Phone:(617) 667-2100
Title Clinical Fellow in Medicine (EXT)
Institution Beth Israel Deaconess Medical Center
Department Medicine
Address Beth Israel Deaconess Medical Center
Department of Medicine - Rabb 430
330 Brookline Ave
Boston MA 02215
Phone 617/667-9278
Fax 617/975-5009
Email
Education & Training
Tufts Medical CenterTufts Medical Center
Residency
Tufts University School of MedicineTufts University School of Medicine
Medical School
Other Training Certifications & Licensure
MA State Medical LicenseMA State Medical License 2011 - 2017
American Board of Internal Medicine
Internal Medicine
Awards, Honors, & Recognition
Merit Award in Palliative Care
Conquer Cancer Foundation of ASCO, 2014
Excellence in Teaching Award
Tufts University School of Medicine, 2014
Notable Teaching Citation
Tufts Medical Center Department of Medicine, 2013
Publications & Presentations
PubMed Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
Einstein, D. J.,DeSanto-Madeya, S.,Gregas, M.,Lynch, J.,McDermott, D. F.,Buss, M. K.; J Oncol Pract. 2017 Jun 01.
Against "Healthy Paternalism" at the End of Life-Reply.
Mathew P, Einstein DJ, Ladin K; JAMA Oncol. 2016-06-01.
The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life.
Einstein, D. J.,Ladin, K.,Mathew, P.; JAMA Oncol. 2016 Feb 26.
Journal Articles
The ethical imperative of healthy paternalism in advance-directive discussions at the end of life Einstein DJ, Ladin K, and Mathew P, JAMA Oncol, 1/25/2016
Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey Einstein DJ, Einstein KL, and Mathew P, J Palliat Med, 1/1/2015
A problematic palsy: an exercise in clinical reasoning Einstein DJ, Trowbridge RL, and Rencic J, J Gen Int Med, 1/1/2015
Abstracts/Posters
"Expanded Prostate Cancer Index Composite-26 Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Lo... Einstein DJ, American Urological Association Annual Meeting, San Diego, CA, 1/1/2016
"Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey." Einstein DJ, ASCO Palliative Care in Oncology Symposium, Boston, MA, 1/1/2014
Lectures
"'Who Am I to Say?' The Role of Residents in Advance Care Planning." Boston, MA - 1/1/2016
Press Mentions
Peuxvn4ujpboexs1qudvDigital Journal
June 2017
Edit your post so everyone know which you are talking about. I just bought more OBMP at .095
Get some at .10. Still a great price.
I did not have that on my radar. Nice little bump there. I did not see any news, did they get some approval or something?
The BID is creeping up and the ASK is holding fast. Much better looking than what we had for a couple of weeks. Only negative anyone has is learningcurve and his CEO sucks comments.
All good news my friend all good news... I think this is very important also.
"This patent is particularly important given the Mexican markets are integral to our business model. "
Getting ready to take off.
Looks like people are finally not giving into the bid. Hold tight and make them buy.
OncBioMune Pharmaceuticals Inc (OBMP) Shares Dealt as Converts Run Off the Books
By Jon Slotnick - June 15, 2017
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) shares have taken a dive in recent weeks. Investors are searching for the answer to one simple question: should one see this as an opportunity or a sign to run away. To answer that question, one needs to understand the market for shares of a stock. It’s very much like an ecosystem.
Not everyone in the tape is buying and selling for the obvious reasoning that most of us can plainly appreciate in a face value manner. Some are involved in processes with roots in logic that have nothing to do with moment-to-moment appraisals of the future stream of earnings or the value according to longer-term fundamentals for the company. In this case, it would appear that one might make a case for convertible debt selling as a sort of artificial depressant of OBMP share prices.
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.
It’s important to keep in mind that OBMP could be interesting as an easy fit for a few different names as far as a take-out candidate.
Just starting with those in the space who have shown a clear interest in development or acquisition of assets that offer potential for market share in the prostate cancer segment, one can easily point to the likes of Seattle Genetics, Inc. (NASDAQ:SGEN), Inovio Pharmaceuticals (NASDAQ:INO), Nymox Pharmaceutical Corporation (NASDAQ:NYMX).
The company also has a portfolio of targeted therapies. OncBioMune Pharmaceuticals, Inc. is headquartered in Baton Rouge, Louisiana.
Driving: A Convertible
The nature of the recent action has the distinct smell of converted shares or hedging shares being unloaded. The only difference between the two is whether or not the conversion has taken place yet.
From the company’s recent 10-Q, we know that, last November, the company issued an aggregate subscription amount of $350,000 to particular investors with the following breakdown in securities: (i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes; and (ii) warrants to purchase 2,333,334 shares of the Company’s common stock at an exercise price of $0.175 (subject to adjustments under certain conditions as defined in the Warrants) which are exercisable for a period of five years from the Original Issue Date.
That’s essentially a burden for the shareholders of the company to bear. Sometimes, the owners of such obligations seek to enable the longer-term success of the company, and sometimes they simply grab the cash they can. In this case, it looks as though the latter strategy has been in place for the past 4-6 weeks.
As this convertible selling is running the tape, the stock is getting pretty beaten up. But it’s important to keep perspective here.
We still have a company with an apparently viable prostate cancer drug pipeline asset which is heading into phase II trials, according to company messaging. That’s a key asset seeking sales status in a $7B market segment.
In addition, we saw the completion of the acquisition of Vitel Laboratorios S.A. de C.V., establishing OncBioMune Mexico S.A. de C.V. as a wholly-owned Mexico City-based subsidiary of OncBioMune as it integrates Vitel’s operations into a component of the Company. The acquisition transitioned OncBioMune into a revenue-generating company with two recently commercialized drugs and a portfolio of others either already licensed or in negotiations for licensing or acquisition.
Sales in Mexico from September 16, 2016 to April 17, 2017 for Bekunis for constipation and Cirkused for stress were approximately US$350,000, exceeding projections for US$155,000 initially forecast for the first seven months at product launch during the third quarter of 2016. The Company anticipates that sales efforts will continue to accelerate and anticipates combined sales in the range of US$750,000 to US$850,000 for the products in 2017.
Given the abject oversold status of the stock on the charts, the company’s vulnerability to the price-per-share distorting impact of convertible debt selling, and the company’s route to near-term top line growth, one has to seriously look at this stock as a potential opportunity from current levels. Market participants unaware of this set of factors may be further distorting the price of the stock by running with the herd. That’s how some of the best opportunities appear in the stock market. It just ain’t easy to spot them in real time. This maybe one of them.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:
I took it as an opportunity to buy more shares. I think we are now on a solid path to revenue and really good upside potential in the long haul. The revenue will help pay the bills through the rest of development. Unlike learningcurve2020 I like the management team. They are solid in the business. Yes I agree they are not the greatest communicators or business men but that is because they are doctors. the business men will come as the revenue grows. I am sure they will add help and experts as they go and can afford it.
OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico
4 minutes ago - DJNF
OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico
MEXICO CITY, MEXICO--(Marketwired - June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and owner of vaccine technology and commercialization of a portfolio of products internationally announced the completion of the acquisition of the sanitary registration and intellectual property rights of Norepinefrine (Norepinephrine) for the Mexican market from Teva Pharmaceuticals Mexico, S.A. de C.V. (Teva), the Mexican subsidiary of Teva Pharmaceuticals, Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day.
Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure. OncBioMune intends to immediately initiate distribution of Norepinefrine throughout its sales channels across Mexico.
The Norepinefrine registration can also be used in other Central and Latin American countries. OncBioMune is conducting its due diligence with plans to selectively launch the drug in other markets in the future.
"The acquisition of Norepinefrine adds the first big generic medicine to our Mexican product bag and we anticipate it will immediately gain traction with physicians," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "We are feeling very confident in our future, given Bekunis(R) had a record sales month in May, the approval of our male fertility product Andfrt(R) two weeks ago and now closing the acquisition of Norepinefrine. Our team is already mobilizing to bring Andfrt(R) and Norepinefrine to market and making sure the supply chain can meet expected demand."
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax(TM), is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Andrew Kucharchuk
225-227-2384
akucharchuk@oncbiomune.com
(MORE TO FOLLOW) Dow Jones Newswires
June 19, 2017 11:55 ET (15:55 GMT)
Okay. I knew that trades will show up after hours to clear books but that is not a true after hours trade even though. But I understand. thanks and I agree with your thoughts. The phase 2 kickoff is coming. I think that will be the second major announcement mentioned.
OTCBB and Pink Sheet Stocks do not trade afterhours. Where did you see that?
I had a call with them two days ago. Call and they answer the phone.
Someone is trying to pump it. I doubt it is OBMP. They also did this when it it the low and before the news. The company had a sell off and is now in recovery so pumpers will take advantage of that but it does not change the actual data of the company. They are now on a solid footing and growth plan. If you are a day trader it might help but as a long it means nothing. My plans are based on company data not hype or doom and gloom post.
Most startups are all debt. They are just now starting revenue.they are still classified as a clinical stage company
Watch the level 2
AqVida has expressed interest in being involved in the development of ProscaVax, OncBioMune's novel therapeutic cancer vaccine currently undergoing clinical trials as a new treatment for prostate cancer. The two companies are contemplating a joint venture in which AqVida would be integral in the clinical development of ProscaVax in Europe, including leading the initiation of clinical studies and manufacturing ProscaVax for use within the highly regulated E.U. market.
Privately held company. details https://www.aqvida.de/english/home/
That is a good question.
Getting Europe on board and a whole other list of approved drugs to now push in Mexico. Hugh news and will have a quick affect on revenues. Also will help get Europe money involved.
OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)
17 minutes ago - DJNF
OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)
BATON ROUGE, LA--(Marketwired - June 15, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces an exclusive distribution and licensing agreement between OncBioMune and AqVida GmbH ("AqVida"), a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, with an emphasis on the field of cancer therapy from their state-of-the-art facility in Dassow, Germany.
As released on 4/26/2017, AqVida granted OncBioMune the rights to several oncology and other generic pharmaceuticals in their portfolio, including imatinib, docetaxel and azathioprine to name a few, for commercialization in the Mexican markets. As an addendum to the agreement, the companies have agreed to expand the portfolio adding Paclitaxel for the treatment of breast, ovarian, lung, bladder, prostate, melanoma, esophageal, Kaposi's sarcoma, as well as other types of solid tumor cancers and Oxaliplatin which is uses to treat colon and rectal cancer that has spread (metastasized).
AqVida has commericialized these products for sale in the European markets. AqVida will support OncBioMune's efforts through providing all requisite documentation for seeking marketing approval in Mexico and manufacturing the products at their GMP-certified facility in Germany.
Additionally, OncBioMune and AqVida are conducting negotiations regarding expanding the exclusive licensing agreement to cover commercialization in the Mexican markets the complete AqVida portfolio of medicines, including several used for treating the most common types of cancer.
Furthermore, AqVida has expressed interest in being involved in the development of ProscaVax, OncBioMune's novel therapeutic cancer vaccine currently undergoing clinical trials as a new treatment for prostate cancer. The two companies are contemplating a joint venture in which AqVida would be integral in the clinical development of ProscaVax in Europe, including leading the initiation of clinical studies and manufacturing ProscaVax for use within the highly regulated E.U. market.
"This agreement helps us become a self-sufficient company and a major generic provider in Latin America," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "AqVida has a strong presence in Europe and in the oncology space, giving us another high-quality partner with deep experience in bringing new drugs to market globally. The relationship with AqVida will allow us to commercialize the products at competitive prices, which we believe will result in capturing a meaningful market share across the board."
"As successful as our generics are throughout Europe, there is a large, untapped market in Mexico for which OncBioMune is an ideal partner to capitalize with its extensive distribution network and experience with the regulatory pathway," said Wolfgang Heinze, CEO at AqVida. "We further see many other synergies between our companies for leveraging resources to introduce our other generics to Mexico and Latin America and to develop ProscaVax for the vast European markets. Approximately 400,000 new cases of prostate cancer are diagnosed each year in Europe and over 92,000 lives are lost annually to the disease. Radical prostatectomy remains a leading therapy and we are of the opinion that a safe and effective new treatment would be warmly welcomed across the entire union. We'd like to be a part of developing such a therapy."
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About AqVida GmbH
AqVida is a German oncology FDF manufacturer that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer. AqVida's expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry. AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio. AqVida is a pharmaceutical company with an impressive track record in fulfilling all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers. AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organization, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax(TM), is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Contact:
OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
akucharchuk@oncbiomune.com
(MORE TO FOLLOW) Dow Jones Newswires
June 15, 2017 12:56 ET (16:56 GMT)
Skipping the 8 and 9 and going right to the 10's!!!
Only issue I have is my funds did not hit my trading account yesterday. I was looking to buy a bunch. Now up 30% and I missed that boat.
Back to .08's as I said. coming soon
I do not consider the recent releases MAJOR. They were just releases about known projects.
Both announcements will be positive not negative.
Blue did you get my PM? I answered your question about the two major announcements coming.
the shares to hoverman and rice are restricted I think.
Also I had several emails back and forth today and he said call if I had any more questions. Gave me his number.
That was exactly what Andrew said today in my email. They are stockholders also.
Why are you even on this board?
good question. I hate when all people have to do is post negative hate messages. even if they had good data to share. Just never makes sense to me but the are on every social media platform. I just ignore it mostly.